Skip to main content

Table 2 Mean hospital lengths of stay (full cohort)

From: A large database study of hospitalization charges and follow-up re-admissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

No. days Initial procedure Follow-up^
Group P value Group P value
V-CBA (n = 6588) rhBMP-2 (n = 9584) V-CBA (n = 1482) rhBMP-2 (n = 2021)
Unadjusted (SD) 3.91 (4.48) 3.67 (3.30) 0.0948 7.97 (12.38) 7.10 (8.52) 0.0694
Adjusted (95% CI) 3.77 (3.66, 3.89) 3.88 (3.77, 3.99) < 0.0001* 7.87 (7.21, 8.53) 7.46 (7.04, 7.89) < 0.0001*
  1. ^Did not include patients who may have received follow-up treatment outside of the Premier Healthcare System
  2. Wilcoxon rank-sum test
  3. Multivariate regression models were adjusted with the following confounds as covariates: race, ethnicity, Charlson comorbidity index, health insurance status, initial admission type, initial admission source, initial discharge status, cage insertion, multiple levels treated, hospital size, hospital teaching status, hospital population served, and hospital region
  4. *Statistically significant